Omeprazole and Occlusion - renal artery - a phase IV clinical study of FDA data
Occlusion - renal artery is found among people who take Omeprazole, especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months.
The phase IV clinical study analyzes which people take Omeprazole and have Occlusion - renal artery. It is created by eHealthMe based on reports of 351,142 people who have side effects when taking Omeprazole from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
351,142 people reported to have side effects when taking Omeprazole.
Among them, 157 people (0.04%) have Occlusion - renal artery.
What is Omeprazole?
Omeprazole has active ingredients of omeprazole. It is often used in gastroesophageal reflux disease. eHealthMe is studying from 360,065 Omeprazole users for its effectiveness, alternative drugs and more.
What is Occlusion - renal artery?
Occlusion - renal artery (a blockage of the major arteries that supply blood to the kidneys) is found to be associated with 1,237 drugs and 722 conditions by eHealthMe.
Number of Omeprazole and Occlusion - renal artery reports submitted per year:
Time on Omeprazole when people have Occlusion - renal artery *:
Gender of people who have Occlusion - renal artery when taking Omeprazole*:
Age of people who have Occlusion - renal artery when taking Omeprazole *:
Common drugs people take besides Omeprazole *:
Common side effects people have besides Occlusion - renal artery *:
Common conditions people have *:
* Approximation only. Some reports may have incomplete information.
Do you take Omeprazole and have Occlusion - renal artery?Check whether Occlusion - renal artery is associated with a drug or a condition
How to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
How severe was Occlusion - renal artery and when was it recovered:
Expand to all the drugs that have ingredients of omeprazole:
Alternative drugs to, pros and cons of Omeprazole:
- Omeprazole (360,065 reports)
Common Omeprazole side effects:
- Fatigue (feeling of tiredness): 22,124 reports
- Diarrhea: 20,344 reports
- Chronic kidney disease: 19,690 reports
- Breathing difficulty: 18,194 reports
- Pain: 15,867 reports
- Drug ineffective: 15,549 reports
- Weakness: 15,449 reports
Browse all side effects of Omeprazole:a b c d e f g h i j k l m n o p q r s t u v w x y z
Occlusion - renal artery treatments and more:
- Occlusion - renal artery (2,552 reports)
COVID vaccines that are related to Occlusion - renal artery:
- Occlusion - renal artery in Moderna COVID Vaccine
- Occlusion - renal artery in Pfizer BioNTech Covid Vaccine
- Occlusion - renal artery in Johnson and Johnson Covid Vaccine
Common drugs associated with Occlusion - renal artery:
- Prevacid: 245 reports
- Aspirin: 223 reports
- Prednisone: 211 reports
- Amlodipine: 199 reports
- Lasix: 191 reports
- Furosemide: 189 reports
- Vioxx: 166 reports
- Plavix: 163 reports
- Omeprazole: 157 reports
- Pantoprazole: 152 reports
All the drugs that are associated with Occlusion - renal artery:
- Occlusion - renal artery (1,237 drugs)
Common conditions associated with Occlusion - renal artery:
- High blood pressure: 461 reports
- Gastroesophageal reflux disease: 167 reports
- Kidney transplant: 161 reports
- High blood cholesterol: 126 reports
All the conditions that are associated with Occlusion - renal artery:
- Occlusion - renal artery (722 conditions)
How the study uses the data?
The study uses data from the FDA. It is based on omeprazole (the active ingredients of Omeprazole) and Omeprazole (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Qvar 40 and Skin Discoloration - Bluish - a second ago
- Stavzor and Depression - a second ago
- Terconazole and Diabetes - 2 seconds ago
- Actonel and Vimizim drug interaction - 4 seconds ago
- Yondelis and Breathing Difficulty - 5 seconds ago
- Benazepril Hydrochloride and Diverticulitis Aggravated - 9 seconds ago
- Eczema and Blood Alkaline Phosphatase Increased - 11 seconds ago
- Irritable Bowel Syndrome and Actinic Keratosis - 24 seconds ago
- Baby Aspirin and Hypertonic Bladder - 32 seconds ago
- Hypothyroidism and Bladder Mass - 33 seconds ago